RINOSINUSIT BILAN KECHUVCHI POLIANGIITLI GRANULEMATOZDA BUYRAKLAR SHIKASTLANISHINING ERTA LABORATOR BELGILARI
DOI:
https://doi.org/10.57231/j.ejohns.2025.4.4.009Ключевые слова:
poliangiitli granulematoz, rinosinusit, siydik sindromi, mikrogematuriya, proteinuriya, buyrak ishtiroki, umumiy siydik tahlili, erta diagnostikaАннотация
Maqsad – rinosinusit bilan kechuvchi poliangiitli granulematoz (PG) bemorlarida siydik sindromi
ko‘rsatkichlarining buyrak ishtirokini erta aniqlashdagi laborator ahamiyatini baholash. Tadqiqotga PG tashxisi
tasdiqlangan va klinik jihatdan rinosinusit bilan murojaat qilgan bemorlar hamda surunkali rinosinusitli nazorat guruhi
kiritildi. Barcha ishtirokchilarda umumiy siydik tahlili bajarilib, miqdor, nisbiy zichlik, рH, leykotsituriya, eritrotsituriya va
proteinuriya darajasi tahlil qilindi. PG bilan og‘rigan bemorlarning 1–2-guruhlarida klinik simptomlar minimal bo‘lishiga
qaramay, mikrogematuriya, yengil proteinuriya va leykotsituriya tez-tez aniqlanib, buyraklar kopto‘
kchalarini shikastlanishining erta belgilarini ifodaladi. Immunosupressiv davolashdan so‘ng 3-guruhda siydik
ko‘rsatkichlari deyarli me’yorlashdi, bu esa o‘z vaqtida qo‘yilgan tashxisning ahamiyatini tasdiqladi. Xulosa qilib, oddiy
umumiy siydik tahlilida qayd etilgan yashirin siydik sindromi rinosinusit fonidagi PG da buyrak ishtirokini erta aniqlash va
oddiy LOR-patologiyalardan farqlash uchun arzon, lekin sezgir marker hisoblanadi.
Библиографические ссылки
Wang R, Wang J, Hu Y, et al. Clinicopathological characteristics and outcomes of anti-neutrophil cytoplasmic antibody-associated vasculitis with acute kidney involvement. Sci Rep. 2021;11.
Wang R, Liu Y, Li X, et al. Hyperuricemia has an important in$ uence on the progression of ANCA-associated renal vasculitis. Sci Rep. 2021;11.
Haraziński P, Piskorz F, Krzanowska K, et al. Granulomatosis with polyangiitis presenting with kidney failure: a case report. Cureus. 2025;17(1).
Marvisi C, Arioli D, Gallelli L, et al. Biomarkers in ANCAassociated vasculitis: clinical utility, pitfalls and their role in the outcomes assessment. Front Immunol. 2025;16:1616837.
Horai Y, Fujimoto S, Amano K, et al. Current diagnosis and treatment of anti-neutrophil cytoplasmic antibodyassociated
vasculitis. J Clin Med. 2025;14(5):1724.
Geetha D, Dua A, Yue H, et al. Effi cacy and safety of avacopan in patients with ANCA-associated vasculitis receiving rituximab in a randomized trial. Ann Rheum Dis. 2024;83(2):223–232.
Jayne DRW, Merkel PA, Schall TJ, Bekker P; ADVOCATE Study Group. Avacopan for the treatment of ANCA-associated vasculitis. N Engl J Med. 2021;384:599–609.
Stacey SD, Holle J, Little MA, et al. Practical management of ANCA-associated vasculitis. Clin Med (Lond). 2024;24(5).
Delvino P, La Rocca G, et al. Systemic vasculitis: one year in review 2025. Clin Exp Rheumatol. 2025;43(Suppl.).
Hunter RW, Welsh N, Farrah TE, Gallacher PJ. ANCAassociated vasculitis. BMJ. 2020;369:m1070.
Wang R, Liu Y, Li X, et al. Long-term outcomes and prognostic factors for survival of patients with ANCAassociated vasculitis. Nephrol Dial Transplant. 2022;37(10).
King C, Harper L. Small vessel vasculitides: an update. Autoimmun Rev. 2024;23(8):103429.
Morales E, Martínez-Morillo M, et al. Recommendations for the diagnosis and treatment of anti-neutrophil cytoplasmic antibody-associated vasculitis. Nefrologia. 2025;45(3).
